Get your free ETF data sample from our comprehensive offerings. Start your free trial→
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
BBP ETF · Virtus LifeSci Biotech Products ETF
The BBP Exchange Traded Fund (ETF) is provided by VIRTUS Investment Partners. It is built to track an index: LifeSci Biotechnology Products Index. The BBP ETF provides physical exposure, so by buying it you actually own parts of all the 63 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update 3/13/2026, 7:59 PM UTC
LIVE
CLOSED
This fund is part ofTomorrow's Treatments1M perf.-2.35%
Last price
$81.25
-0.53%
1M perf.
+0.58%
1M flows
+€3.5M
AuM
€43M
E/R
0.79%
Rating
ESG Consensus®
BBP
$81.25
-0.53%
Performance & flows
Segment for quartile rank
December 12, 2025 → March 12, 2026
Create a free account to view the flows graph
BBP
$81.44
+3.36%
Tomorrow's Treatments
+0.49%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +0.58%  | +3.36% | +35.25%  | +67.03% | +48.61% | -4.33% | +2.10% | +2.10% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
CUSIP
26923G202
ISIN
US26923G2021
AuM
€43M
E/R
0.79%
Replication rating
ESG Consensus®
More details
NAV
3/12/2026
$81.44
1D NAV change
-3.33%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
63
Inception date
12/16/2014
Jurisdiction
United States
Distribution
United States
Legal structure
Statutory Trust
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index, which tracks the performance of biotechnology companies with at least one drug therapy approved by the FDA.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSimilar ETFs in your region
XBI
1M perf.
-0.80%
E/R
0.35%
CURE
1M perf.
-0.02%
E/R
0.45%
XHE
1M perf.
-5.52%
E/R
0.35%
ARKG
1M perf.
-7.14%
E/R
0.75%
AAKG
1M perf.
-6.84%
E/R
0.75%
Advertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +3.36% | +35.25% | +67.03% | +48.61% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
Built for professionals: access exclusive risk metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseExposure
Countries
USA
90.82%
Cayman Islands
1.80%
United Kingdom
1.72%
Bermuda
1.71%
Switzerland
1.60%
Canada
1.54%
Unavailable
0.80%
Sectors
Health Care
88.88%
Unavailable
11.12%
Diversification
Total weight of top 15 holdings out of 63
Top 15 holdings
Data as of January 31, 2026
DAY ONE BIOPHARMACEUTICALS
DYNAVAX TECHNOLOGIES
AMICUS THERAPEUTICS
IOVANCE BIOTHERAPEUTICS INC
ARDELYX
AXSOME THERA CMN STK
BIONTECH SE ADR
GILEAD SCIENCES
Create a free account to view top holdings
KRYSTAL BIOTECH INC
HALOZYME THERAPEUTICS
US52635N1037
AMGEN-T
THERAVANCE BIOPHARMA
INCYTE
EXELIXIS
Create a free account to view top holdings
Built for professionals: access exclusive exposure metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseSustainability
Integrates ESG criteria
No
SDG
ESG Consensus® by Conser
Data as of December 31, 2025
MethodologyOur partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about BBP ETF's sustainability, based on their methodology.
ESG Consensus®
ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.
BBP’s has a Final Sustainability Grade of either A+, A, or A-.
A+
A
A-
B+
B
B-
C+
C
C-
D
This fund’s exact Final Sustainability Grade is available in Trackinsight Enterprise.
Learn more about Trackinsight EnterpriseHoldings review
89.91% of holdings have positive scoring
10.90% of holdings have negative scoring
11.59%
56.95%
21.37%
6.39%
Consensus levels
Strong
Medium
Weak
Built for professionals: access exclusive sustainability metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseReplication
Trackinsight replication rating:
Replication quality
Calculated over 12m, as of February 27, 2026
Tracking error
Tracking difference
Replication information
Index
LifeSci Biotechnology Products Total Return Index - USD
Index ticker
LSCIBP Index
Index dividend policy
GTR
Replication method
Replication model
Built for professionals: access exclusive replication metrics in Trackinsight Enterprise.
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseIssuer
VIRTUS Investment Partners
VIRTUS Investment Partners ID Card
Number of funds
22
Total AuM
€2.36B
Expense ratio range
0.25% - 9.86%
Average expense ratio
0.9614%
Top 5 funds by VIRTUS Investment Partners
| AuM | ||
|---|---|---|
UTES | Virtus Reaves Utilities ETF | €1.22B |
NFLT | Virtus Newfleet Multi-Sector Bond ETF | €349M |
SEIX | Virtus Seix Senior Loan ETF | €207M |
JOET | Virtus Terranova U.S. Quality Momentum ETF | €198M |
VABS | Virtus Newfleet ABS/MBS ETF | €68M |
Frequently asked questions about BBP
What does Virtus LifeSci Biotech Products ETF, BBP, invest in?
BBP is a Passive ETF. This ETF provides exposure to Equally Weighted US Equities.
Which benchmark or index does BBP replicate?
BBP tracks the LifeSci Biotechnology Products Total Return Index - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of BBP?
BBP carries a total expense ratio (TER) of 0.79%, indicating the annual cost for holding the fund.
When was BBP launched?
BBP was introduced to the market on December 16, 2014. It trades on United States
Who is the ETF issuer of BBP?
Virtus LifeSci Biotech Products ETF, BBP, is provided by VIRTUS Investment Partners. Learn more about VIRTUS Investment Partners here.
What is the current assets under management (AUM) of BBP?
BBP oversees €43M in assets as of March 12, 2026.
How has BBP performed lately?
Based on data from March 12, 2026, BBP returned 0.58% over the past month, 3.36% over the last three months and 2.10% year-to-date.
What are the latest inflows or outflows for BBP?
As of March 12, 2026, BBP recorded net flows of +€3.4M over the last month and +€3.4M year-to-date.
Does BBP distribute dividends?
BBP follows a distributing dividend policy, meaning it pays out income to investors.
What are the main country or region exposures of BBP?
As of January 31, 2026, BBP has significant geographic allocations in USA, Cayman Islands and United Kingdom.
In which sector or theme does BBP invest in?
As of January 31, 2026, BBP focuses largely on Health Care.
How many securities does BBP hold and how diversified is it?
As of January 31, 2026, BBP holds 63 positions in its portfolio, with 30.11% of assets concentrated in its top 15 holdings.
What are the main positions in BBP?
As of January 31, 2026, BBP top three holdings include DAY ONE BIOPHARMACEUTICALS, DYNAVAX TECHNOLOGIES and AMICUS THERAPEUTICS.
What is the base currency of BBP?
The base currency of BBP is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
